Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

Literature DB >> 3797686

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

Abstract

Brain MAO-B activity increases with age. The rate of increase varies in different brain regions. Brain MAO-A activity does not change with age in man and is decreased in the rat. Brain MAO-B activity in AD/SDAT is higher than in age-matched controls. The increased MAO-B activity in aging is due to an increased concentration of otherwise unchanged extrasynaptosomal MAO-B. The increase in brain MAO-B activity with age and in AD/SDAT is more pronounced in white matter than in gray matter. Platelet MAO is increased in patients with AD/SDAT.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1986 PMID： 3797686 DOI： 10.1016/0278-5846(86)90023-0

Source DB: PubMed Journal: Prog Neuropsychopharmacol Biol Psychiatry ISSN： 0278-5846 Impact factor: 5.067

Keyword Cloud
Cited

19 in total

1. Expression of monoamine oxidase B activity in astrocytes of senile plaques.

Authors: S Nakamura; T Kawamata; I Akiguchi; M Kameyama; N Nakamura; H Kimura
Journal: Acta Neuropathol Date: 1990 Impact factor: 17.088

2. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

Authors: Lydia M Mexas; Virginia R Florang; Jonathan A Doorn
Journal: Neurotoxicology Date: 2011-04-14 Impact factor: 4.294

3. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

Authors: S M Aquilonius; S S Jossan; J G Ekblom; H Askmark; P G Gillberg
Journal: J Neural Transm Gen Sect Date: 1992

4. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors: M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal: J Neural Transm Gen Sect Date: 1995

5. Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

Authors: Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Journal: Brain Res Date: 2012-07-31 Impact factor: 3.252

6. Development of monoamine oxidase activity and monoamine effects on glutamate release in cerebellar neurons and astrocytes.

Authors: L Hertz; L Peng; E Hertz; B H Juurlink; P H Yu
Journal: Neurochem Res Date: 1989-10 Impact factor: 3.996

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

1. Expression of monoamine oxidase B activity in astrocytes of senile plaques.

2. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.

3. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

4. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

5. Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

6. Development of monoamine oxidase activity and monoamine effects on glutamate release in cerebellar neurons and astrocytes.

7. Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease.

Review 8. Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Review 9. Perspectives on MAO-B in aging and neurological disease: where do we go from here?

10. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice.